Innate Pharma S.A. completes €30 million private placement of Ordinary Shares

Client(s) Innate Pharma S.A.

Jones Day advised Innate Pharma S.A., a global clinical-stage biotechnology company developing immunotherapies for cancer patients, on the U.S. aspects of its €30 million offering of Ordinary Shares to U.S. and international investors.